ArticleMedicine2026
Developing and validating a SNARE-based prognostic model to forecast outcomes and immune microenvironment in lung squamous cell carcinoma.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SNARE-related genes (SRGs), which mediate membrane fusion events, play critical roles in the development and advancement of cancer. The aim of this research was to develop a prognostic signature based on SRGs for lung squamous cell carcinoma (LUSC) and assess the biological functions of associated SRGs. Transcriptomic and clinical data for LUSC were obtained from public databases. Least absolute shrinkage and selection operator regression generated a risk signature, which was analyzed for associations with clinicopathological features, immune microenvironment, and drug sensitivity. A nomogram was developed based on SRGs-derived signature. Biological function analysis was performed using RNA interference techniques, colony formation assays, transwell assays, and wound healing assays. Ten significantly prognostic SRGs were identified and employed to generate a risk score for LUSC. This signature categorized LUSC patients into the high- and low-risk cohorts, demonstrating notable variations in clinical-pathological features, immune infiltration patterns, gene expression profiles, and responses to drug sensitivity. The developed signature proved itself as an independent predictor of LUSC prognosis, exhibiting robust predictive power for survival outcomes. A nomogram model combining the signature with smoking history showed superior performance and clinical applicability. Knockdown of the bet1 golgi vesicular membrane trafficking protein (BET1) gene in LUSC cells significantly enhanced clonogenic capacity and promoted cancer cell migration and invasion. Our study substantiated the potential clinical significance of a risk signature derived from SRGs in LUSC' prognosis prediction. It provided novel insights into the interactions among SRGs, tumors, and immunity, potentially contributing to the advancement of precision medicine for LUSC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.